Lv2
150 积分 2024-06-07 加入
Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial
3天前
已完结
MetALD: new opportunities to understand the role of alcohol in steatotic liver disease
15天前
已完结
Steatotic liver disease
20天前
已完结
Lineage-specific intolerance to oncogenic drivers restricts histological transformation
1个月前
已完结
Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study
2个月前
已完结
The design for a phase II, randomized, multicenter study of ctDNA-guided treatment with furmonertinib combined therapy or furmonertinib alone for untreated advanced EGFR mutant non-small cell lung cancer patients: The FOCUS-C study
2个月前
已完结
Efficacy and safety of taletrectinib in patients with advanced or metastatic ROS1+ non–small cell lung cancer: The phase 2 TRUST-I study
2个月前
已关闭
Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1–2 trial
2个月前
已完结
Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1–2 trial
2个月前
已完结
Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial
2个月前
已完结
皖公网安备34019202002308
